Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CNTN4 antibody GENA-104A16

An affinity-matured humanized monoclonal antibody directed against the inhibitory immune checkpoint protein contactin 4 (contactin-4; CNTN4), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CNTN4 monoclonal antibody GENA-104A16 targets and binds to CNTN4 expressed on cancer cells. This abrogates CNTN4-mediated immune suppression, decreases regulatory T cells (Tregs), and may restore and increase CD4+ and CD8+ T-cell proliferation and activation and the release of inflammatory cytokines. This may lead to a cytotoxic T-lymphocyte (CTL)-mediated killing of tumor cells that overexpress CNTN4. CNTN4 negatively regulates T-cell activity through binding with amyloid precursor protein (APP) on T cells. It is overexpressed on a variety of tumor cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-contactin-4 monoclonal antibody GENA-104A16
Code name:GENA 104A16
GENA-104A16
GENA104A16
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search